Dyne Therapeutics (NASDAQ:DYN) & Acerus Pharmaceuticals (OTCMKTS:ASPCF) Financial Analysis

Dyne Therapeutics (NASDAQ:DYN) and Acerus Pharmaceuticals (OTCMKTS:ASPCF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Profitability

This table compares Dyne Therapeutics and Acerus Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-57.46%	-51.62%
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%

Institutional & Insider Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Dyne Therapeutics and Acerus Pharmaceuticals”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$235.94 million	($3.56)	-6.96
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06

Acerus Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Dyne Therapeutics and Acerus Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	0	1	10	2	3.08
Acerus Pharmaceuticals	0	0	0	0	0.00

Dyne Therapeutics currently has a consensus target price of $49.91, indicating a potential upside of 101.57%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Acerus Pharmaceuticals.

Risk and Volatility

Dyne Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Acerus Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Summary

Dyne Therapeutics beats Acerus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.